Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 12 - Any |
| Updated: | 12/12/2018 |
| Start Date: | August 28, 2015 |
| End Date: | August 25, 2017 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared
to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.
to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.
To evaluate the therapeutic efficacy and safety of dsxs topical spray, 0.15% (Taro
Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals,
U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.
Pharmaceuticals, U.S.A., Inc.) compared to a Placebo (vehicle) spray (Taro Pharmaceuticals,
U.S.A., Inc.) in patients with mild to moderate plaque psoriasis.
Inclusion Criteria:
- male and non-pregnant females, 12 years of age or older, with a confirmed diagnosis of
mild to moderate plaque psoriasis
Exclusion Criteria:
- patient is< 12 years old.
We found this trial at
1
site
Click here to add this to my saved trials
